GLP-1 drugs unlock health benefits beyond weight loss

GLP-1 drugs such as Ozempic and Wegovy are proving their value goes far beyond shrinking waists: trials show they can reduce sleep-apnea interruptions, lower the risk of kidney failure in type 2 diabetes with CKD, reverse fatty liver inflammation, ease knee pain in obesity, and lower major cardiovascular events even in people without diabetes. The broader takeaway is that these medicines may offer broad health benefits beyond weight loss, a reminder of medicine’s “happy accidents.” Yet they come with caveats—weight loss often includes lean muscle loss, cost and access barriers persist, and social stigma around weight remains a challenge.